Popular weight-loss drugs linked to sudden vision loss, research suggests
Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period.
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide.
Popular Weight-loss Medication Could Relieve Painful Arthritis Symptoms, Doctors Report
Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAION, compared to 19 people in the comparison group.
The Ohio-based researchers also noted an increased risk of developing "other optic nerve disorders," identified in 93 patients.
Read On The Fox News App
Although the second study did not observe a "statistically significant difference" in NAION in GLP-1 drug users, there was a small increase in diabetic retinopathy, an eye disease that can damage the retina.
Diabetic Patients Taking Glp-1s May Face Increased Risk Of Eye Disease, Study Suggests
While individuals with type 2 diabetes on GLP-1s showed a modestly increased risk of diabetic retinopathy, the researchers concluded that fewer patients experienced sight-threatening complications from the disease.
"These findings suggest that all patients with type 2 diabetes treated with GLP-1 RAs, regardless of preexisting diabetic retinopathy, should be regularly screened and monitored for potential complications," the study authors concluded.
Sue Decotiis, M.D., a medical weight loss doctor in New York City, said she believes more studies are required to confirm the association between these drugs and vision loss, as these studies report some conflicting results.
"NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies," Decotiis, who was not involved in the research, told Fox News Digital. "We need more studies for certain."
Diabetic patients already face a high incidence of eye disease related to blood flow and nerve damage, the expert noted.
"Eye complications are often directly related to the degree or lack thereof of diabetes control."
Click Here To Sign Up For Our Health Newsletter
In most cases, GLP-1 drugs reduce the severity of type 2 diabetes, therefore reducing the incidence of eye diseases, Decotiis noted.
These drugs have also been shown to reduce the risk of cardiovascular disease, like hypertension, and to improve circulation, which can improve eye health.
For diabetics who are starting a GLP-1, Decotiis recommends having an exam done by an ophthalmologist and scheduling follow-up exams throughout treatment.
"We should take precaution with methodical ophthalmic care for diabetics on these drugs," Decotiis said. "However, let's not throw the baby out with the bath water."
For more Health articles, visit www.foxnews.com/health
Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital.
"Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S."
"Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events."Original article source: Popular weight-loss drugs linked to sudden vision loss, research suggests
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
26 minutes ago
- Wall Street Journal
Eli Lilly to Raise U.K. Price of Mounjaro for Out-of-Pocket Patients
Pharma giant Eli Lilly said it is negotiating to raise drug prices in Europe, starting in the U.K. with the weight-loss drug Mounjaro, so that it can comply with the Trump administration's goal of bringing down prices in the U.S. Lilly said Thursday that it has an agreement with the U.K. government to raise the list price of Mounjaro for patients who pay for it out-of-pocket. Lilly will more than double the list price of Mounjaro's highest dose from about $165 to about $446. The new price is in line with the prices paid in the rest of Europe and other developed countries, Lilly said.
Yahoo
38 minutes ago
- Yahoo
Ozempic didn't work for me. I was furious
I'm 46 years old and I have been on a diet since I was 11. For as long as I can remember, eating has given me comfort. As a kid, I lied to my friends' parents so I could eat a second dinner at their house. I've never wanted just one cookie – I'd eat 12 and only stop when I felt physically ill, and sometimes not even then. In nearly every photo of me as a teenager I'm wincing, sucking in my stomach, trying to pose. I never really enjoyed the taste of these foods, nor was I happy with myself after eating them. They came with a side of guilt: you don't deserve this. This relentless food noise trapped me in a cycle of wanting to eat, then shaming myself for doing it. I spent inordinate energy hating my too tall, too big body. I always felt simultaneously like not enough and too much. Now, GLP-1 drugs like Ozempic, Wegovy and Mounjaro are being hyped as an easy fix to obesity. Their manufacturers have experienced significant revenue growth credited to the drugs' popularity; for instance, Eli Lilly recently announced 38% yearly growth, credited in part to sales of Zepbound and Mounjaro. Media headlines tout the changes in weight and appetite for those who take them. But what if the 'miracle' doesn't work for you? *** Being diagnosed with diabetes at age 27 threw me deeper into a shame spiral. At the time, my doctor clinically defined me as obese. That, along with the prognosis of a deficient pancreas, felt like punishment for decades of failing to control my overeating. Given my family history of diabetes – my grandpa had it – the doctor diagnosed me as type 2 and recommended dramatic lifestyle adjustments, including carb counting and daily exercise. She also did an A1C test, which measures average blood sugar levels for three months. A non-diabetic's result would be under 5.7%. Mine was 7.7%. This diagnosis felt like being sentenced to lifelong obsession. Food already controlled me, and now it had even more power. Over the next five years, I worked with a nutritionist and psychotherapist. I trained for a 200-mile relay race with friends. I did Weight Watchers, went to Overeaters Anonymous, worked the 12-step program, and used apps like Noom and My Fitness Pal. I lost 50lb. Still, I remained overweight according to the BMI chart, and my A1C didn't budge, which confounded my primary care doctor. Related: I'm not diabetic – should I be using a glucose monitor? She referred me to an endocrinologist who specialized in metabolic health. Six months later, when my appointment finally arrived, my A1C had shot up to 9.1%. That should not have happened while I shed pounds. She declared I was misdiagnosed: type 2 diabetics' bodies make insulin, which helps regulate blood sugar, but don't use it effectively. But I was actually type 1, an autoimmune condition where the body stops producing insulin. I would be dependent on insulin injections from that point forward. Living with diabetes was taxing. I had to order a continuous glucose monitor (CGM), pen needles, insulin vials and other items – but via a specialty supplier rather than a standard pharmacy, for insurance purposes. I had to procure pre-authorization forms for medication and attend required half-day training sessions every time I wanted to try a different insulin pump or when my insurance changed. But in 2018, after five years of effort, my A1C settled in at 5.9% – a happy result for me and my doctor. But to get to a weight my doctor would approve, I still had to lose 30lb. She started me on a new drug called Ozempic. Like most people at that point, I'd never heard of it. She said it was only technically approved for type 2 patients – but some who were overweight with type 1, like me, were taking it to help with weight loss. Over the next four years, my doctor and I gradually increased my Ozempic dosage and eventually were pleased with the results: when I woke in the morning my fasting blood sugar reading was finally within the recommended range of 80-120 on my CGM. I was able to reduce my regular insulin usage. But my weight didn't change. I continued my healthier eating habits and exercised regularly with cycling, yoga and running. Still, the scale didn't move. *** In 2022, when Ozempic was becoming a household name, I suddenly had two problems. First, my doctor confirmed I was already on the highest available dose, so taking more wouldn't help me lose weight. Second, because the drugs were now approved for general weight loss, I might have trouble filling my prescription. A global shortage followed, and I went four months without, eventually switching to Mounjaro because it was available. The meds are highly effective for a majority of patients but there is still a percentage who don't lose … body weight Veronica Johnson My already-thin friends started taking GLP-1s, and I couldn't avoid chatter about the 'skinny shot'. 'I'm not even hungry! I don't even think about food!' they'd say. But I didn't experience this quieting of the voices in my head telling me I was hungry all the time, and I wondered why. I was furious. As my friends celebrated their new bodies, I wondered, again, what was wrong with mine. My diabetes was under control, but I was also existing at the margins of a miracle. An estimated 15% of all GLP-1 users are so-called 'non-responders' to the weight loss effect, according to Atlanta-based physician Dr Cristina Del Toro Badessa. Lucas Veritas, a GLP-1 user from Montreal and author of The GLP-1 Effect newsletter, highlighted clinical trials showing that approximately 13% of people taking semaglutide (the active ingredient in Ozempic and Wegovy) and about 9% of those taking tirzepatide (found in Mounjaro and Zepbound) did not lose more than 5% of their body weight. 'The meds are highly effective for a majority of patients but there is still a percentage who don't lose a clinically significant percentage of body weight. Everyone's physiology is a little different,' said Veronica Johnson MD, an obesity medicine specialist in Chicago. Recent research has identified a gene that may help predict who will successfully lose weight with GLP-1 medications. Related: The radical practice of eating what you want Additionally, according to a recent study comparing GLP-1 medications to bariatric surgery, 'real world' cohorts lost less weight than what drug companies reported in their trials: about 5% of their body weight, compared with the 15% reported for semaglutide and the 20–25% for tirzepatide in pharma-funded studies. Nicoletta LaMarca-Sacco, 56, a former Ozempic user in New York, also didn't lose weight after a year of use. 'I've always been a squishy mom and will continue to be,' she said. 'It just didn't work for me.' She expected the drug would quiet more of the internal chatter telling her she needed to snack. 'It did help, but only to a small degree,' she said. 'When we consider these drugs, they need to be combined with other markers of good health like diet, exercise, even stress management,' said Dr Raj Dasgupta, an ABIM Quadruple board-certified physician in Los Angeles. He said his patients sometimes had unrealistic expectations about how quickly and dramatically they will drop extra pounds. He explained that for someone who is overweight, shedding even a small amount of weight can improve heart and kidney function, adding: 'The bar has been set too high for weight loss.' 'What's dangerous,' Badessa said, 'is the dominant societal narrative that these are 'magic shots' for weight loss.' Veritas agreed: 'Expectations are sky-high. People see all the before/after photos and expect an easy ride.' 'It feels similar to any other time the diet industry has thrown marketing momentum behind one particular 'fix',' Virginia Sole-Smith, author of Fat Talk, told me about the current hype. 'There's excitement that we've found a 'silver bullet', then it silences any other narratives and experiences about it.' Related: What is metabolic syndrome – and do we really need to worry about it? I had definitely been looking for an elixir to rid me of body mass. Then I discovered that diabetes itself might be the reason I wasn't losing weight. Andrew Koutnik, a metabolic research scientist, said that GLP-1s typically lead to significant weight loss for people with obesity (15-25% of their body weight). However, people with diabetes generally lost less weight, proportionally: for type 2, an average of 8-11%; for type 1, about 8-12%. 'While we don't know why this is occurring, prior data suggests the drug's metabolic effects may be tied to how well the body manages glucose,' Koutnik said. GLP-1s are designed to coax the body into making and using insulin more efficiently, he explained. But for someone with type 1 diabetes, meaning their pancreas cannot make insulin, that's like installing a turbocharger on a car with no engine – there's nothing to boost. That said, he clarified, these drugs aren't entirely useless for people with type 1. GLP-1s slow digestion and suppress appetite, which can lead to fewer snacks and less carb-heavy meals. That might nudge blood sugar in the right direction, but it's more of a side-effect. 'The actual impact on blood sugar control is minimal: less than a 1% drop in A1C,' Koutnik explained. *** The psychological fallout of being a non-responder can be devastating. It was more fodder for my destructive inner dialogue: Why won't my body just comply? Alyson Curtis, a therapist based in New York, works with patients who feel isolated as they see others losing weight and don't have the same result. I told her how unfair it felt and she agreed the loss of agency can be a lot to process. 'I hear the 'thin fantasy' constantly from patients – it's a dream to fit into societal norms,' Curtis added, 'but what they're really saying is they want to be accepted, cherished, adored.' She helps patients reframe success to focus on healthy outcomes beyond weight loss – like how the Health at Every Size (HAES) movement centers on overall wellbeing. It feels similar to any other time the diet industry has thrown marketing momentum behind one particular 'fix' Virginia Sole-Smith Still, these drugs are here to stay. Johnson pointed to recent innovations like CagriSema, a compound drug bringing together an amylin agonist and a GLP-1. In trials, CagriSema helped reduce blood sugar spikes after meals and can also contribute to weight loss. 'The hormone called amylin is normally released by the same cells that make insulin – which type 1 diabetics lack,' Koutnik said. He added that amylin helps slow digestion and also lowers levels of glucagon, which could help better manage blood sugar. Society seems to have rewritten ideas about health, worth and willpower through the lens of these astonishing drugs. I figured I could, too. I've tried to quiet the inner voice that's shaming me into thinking I'm a failure for not losing more weight. Forging self-acceptance from deep frustration, I am realizing there is nothing inherently 'wrong' with my body – I am simply among those for whom the current medications produce a partial benefit. Learning that I'm not alone has helped curb my body shame. I am grateful that GLP-1s have helped me with blood sugar control, minimizing my risk of complications from diabetes. 'When we focus on the miracle weight loss narrative, we ignore their real value in helping people with diabetes, adding to the discourse of body shaming, which is never health-promoting,' said Sole-Smith. I've been trying to shift my focus from weight loss to improving my relationship with food. For me, that's learning to eat with more intention and maybe even a little joy. Hopefully, I can come to appreciate my right to the occasional indulgence without self-recrimination. And on my next birthday, I want to celebrate with the most delicious symbol of self-acceptance: a guilt-free piece of cake.
Yahoo
an hour ago
- Yahoo
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors (GPCR) targets within the cardiometabolic and obesity space. The collaboration between the two companies will allow Eli Lilly the exclusive rights to develop and commercialise compounds discovered on Superluminal's AI and machine learning (ML)-powered platform. In return, Superluminal is eligible to receive up to $1.3bn, which includes upfront and near-term payments, an equity investment, development and commercial milestones, as well as tiered royalties on net sales. Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in September 2024. The $1.3bn partnership with Eli Lilly marks a steep growth trajectory for the company that launched in 2023 with $33m in seed funding. For Eli Lilly, the research pact marks a bolstering of its already successful cardiometabolic and obesity portfolio. Known under the brand names Mounjaro and Zepbound, tirzepatide activates two proteins in the GPCR family – glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Eli Lilly's two drugs earned a combined $8.57bn in Q2 2025 alone. Neither Lilly nor Superluminal confirmed whether more GIP or GLP-1 goalposts will be included in their collaboration, stating the platform will be only used to find 'undisclosed GPCR targets'. Superluminal states on their website that: 'Despite their importance, many GPCRs remain unexplored as drug targets, and we often lack detailed structural information.' Eli Lilly's main rival in the GLP-1RA space, Novo Nordisk, signed a GPCR deal of its own earlier this year. The Danish drugmaker outlaid $2.2bn in a deal with US biotech Septerna in May with the aim of finding and developing small-molecule drugs in obesity and diabetes. This is not the first time Lilly has put money behind GPCR projects. In December 2022, the company signed a partnership worth up to $694m with Tokyo-based Sosei for GPCR drug development, also in the diabetes and metabolic disease space. Superluminal CEO Cony D'Cruz said: '[With Eli Lilly], we aim to develop next-generation medicines that address the urgent and growing global burden of cardiometabolic disease. "We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity, and we are committed to bringing safe, efficacious, novel treatments to patients affected by these challenging conditions.' Superliminal's pipeline comprises entirely of pre-clinical candidates. The most advanced is an asset that targets the melanocortin 4 receptor (MC4R), a protein that plays a role in regulating appetite and body weight. "Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
